Lupin Ltd

Lupin Employee Stock Options

Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.

Lupin Product Launch

Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.

Lupin Employee Stock Options

Lupin Limited allotted 30,967 equity shares under its Employee Stock Option Plan. This allotment increases the company's total issued and paid-up equity share capital.

Lupin Other Announcement

Lupin Limited received an ESG rating of '60' ('Adequate' category) from ESG Risk Assessments & Insights Limited, which was assigned independently without company engagement.

Lupin Partnership

Lupin Limited's subsidiary VISUfarma B.V. signed an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI™ in Europe. The deal includes potential consideration of €75 million.

Value

₹832.5 Cr

Execution

Initial term until 20th anniversary of first commercial sale

Lupin Management Change

Lupin Limited announced the sad demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, on August 17, 2026.

Lupin Regulatory Approval

Lupin received U.S. FDA approval for Sodium Zirconium Cyclosilicate for Oral Suspension. The drug treats hyperkalemia in adults.

Lupin Earnings Call Transcript: Key Takeaways

Lupin reported record Q1 FY27 revenues of ₹8,277 crore with strong EBITDA margins of 30%. Growth was broad-based across US and India, though management expects near-term US moderation due to increased competition in key products.